Renovaro Inc. (RENB) - 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Renovaro Inc. (formerly Renovaro Biosciences Inc.) for the period ended December 31, 2024. The company operates through two primary segments: Renovaro Biosciences (RENB), focusing on allogeneic cell and gene therapies for cancer and infectious diseases, and Renovaro Cube (RENC), an AI-driven healthcare technology company focused on early cancer detection. The company is a pre-revenue, pre-clinical entity.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,252,394) | $(51,464,429) |
| Loss Per Share (Basic & Diluted) | $(0.04) | $(0.32) |
| Cash and Cash Equivalents | $311,764 | $311,764 |
| Working Capital Deficit | $(26,898,493) | $(26,898,493) |
| Total Assets | $111,340,272 | $111,340,272 |
| Total Liabilities | $29,280,954 | $29,280,954 |
| Goodwill | $107,999,273 | $107,999,273 |
Cash Flow (Six Months Ended Dec 31, 2024):
- Net cash used in operating activities: $(4,576,052)
- Net cash used in investing activities: $0
- Net cash provided by financing activities: $4,620,162
Material Changes vs. Prior Period
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $47,614,729 for the six months ended December 31, 2024, driven by a decline in the estimated fair value of the RENC reporting unit due to the company's inability to raise capital. No impairment was recorded in the prior year period.
- Contingent Consideration: The fair value of the contingent consideration liability related to the Renovaro Cube acquisition decreased by $6,660,000 during the six-month period, resulting in a gain that partially offset operating losses. The liability balance dropped from $12,310,000 to $5,650,000.
- Operating Expenses: Total operating expenses increased by 340% year-over-year for the six-month period, primarily due to the goodwill impairment. Excluding impairment, general and administrative expenses decreased by 19% and R&D expenses decreased by 54% compared to the prior year.
- Debt: The company increased its debt load through various promissory notes with related parties and third parties, with notes payable to related parties increasing significantly to $4,885,000.
Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that the company's substantial recurring losses, cash usage, and working capital deficit raise substantial doubt about its ability to continue as a going concern for one year following the report date. The company has only $311,764 in cash and is dependent on additional equity or debt financing to fund operations.
Legal Proceedings:
- Securities Class Action: A settlement stipulation was signed on November 8, 2024, regarding the "Chow Action." The court is considering preliminary approval.
- Derivative Litigation: Multiple federal and state derivative actions remain pending or stayed, alleging breaches of fiduciary duty and mismanagement.
- Company Lawsuits: The company is actively litigating against former partners (G Tech, SRI, Wittekind) alleging a scheme to falsify study results, seeking recovery of approximately $25 million. Trial dates have been set for May 2025.
- Investor Rights Dispute: Litigation with Weird Science and Wittekind regarding registration rights is ongoing, with an appeal pending following a dismissal of a derivative complaint.
Subsequent Events: In January and February 2025, the company issued new promissory notes totaling $900,000 and entered into a credit agreement with a capacity of up to $4,000,000.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $311,764 cash balance against the $26.9 million working capital deficit and upcoming debt maturities.
- Financing Status: Confirm the status of the $4 million credit facility entered into in February 2025 and any new equity raises required to sustain operations.
- Legal Exposure: Monitor the outcome of the May 2025 trial regarding the $25 million fraud claim and the final approval of the securities class action settlement.
- Goodwill Valuation: Assess the sustainability of the remaining $108 million goodwill balance given the recent impairment and the company's capital constraints.
- Related Party Debt: Review the terms and maturity dates of the $4.9 million in notes payable to related parties, which pose a significant refinancing risk.